Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 131 of 6351
-
New drug could extend window for treating deadly stroke
Disease control Recruiting nowPatients presenting to the emergency department with an acute ischemic stroke due to basilar artery occlusion within 24 hours of stroke onset will be assessed to determine their eligibility for randomization into the trial. If the patient gives informed consent they will be rando…
Phase 2/3 • Sponsor: University of Melbourne • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Breakthrough shot shields babies from deadly RSV
Prevention CompletedThe purpose of this study is to evaluate the Safety and Efficacy of Nirsevimab, in Healthy Preterm and Term Infants in China
Phase 3 • Sponsor: AstraZeneca • Aim: Prevention
Last updated Jun 27, 2026 12:02 UTC
-
Artificial heart trial aims to keep patients alive until transplant
Disease control Recruiting nowThe safety and performance of the Aeson TAH system have been demonstrated for the CE mark approval in December 2020. The purpose of this post-market clinical investigation is to confirm the safety, performance and effectiveness of the Aeson TAH system when used in routine care by…
Sponsor: Carmat SAS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Can a daily pill outsmart resistant lung cancer mutations?
Disease control Recruiting nowThis study is a single center cohort study to access the anti-tumor efficacy, safety and tolerability of DZD9008 in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) sensitizing mutations and EGFR unc…
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
A simple breath test after a heart attack could prevent dangerous bleeding
Prevention OngoingBackground: Potent antithrombotic therapy has improved prognosis for patients with acute myocardial infarction (MI) significantly, however, at a price of increased bleeding risk. Helicobacter pylori (H. pylori) infection commonly causes upper gastrointestinal bleeding (UGIB). If …
Sponsor: Karolinska Institutet • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail aims to outsmart resistant lung cancer
Disease control OngoingThe purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in participants with locally advance…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Daily pill could offer new hope for weight loss in east asian adults
Disease control CompletedNovo Nordisk are doing this study to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants' body weight. Participants will either get semaglutide tablets (new medicin…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could steroids help kids recover from stroke?
Disease control Recruiting nowThis clinical trial deals with focal cerebral arteriopathy and childhood stroke, a rare but devastating condition. Focal cerebral arteriopathy (FCA) is an inflammatory vessel wall disease provoked by infection and there is increasing evidence that inflammatory processes play a c…
Phase 3 • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Can a modified herpes virus fight recurrent brain tumors?
Disease control CompletedIn the first phase, it mainly explores the safety, tolerability and preliminary effectiveness of two doses of OH2 injection in the treatment of patients with recurrent central nervous system tumors; to evaluate the biodistribution and virus shedding of OH2 injection administered …
Phase 1/2 • Sponsor: Binhui Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Gene therapy breakthrough? new treatment aims to fix sickle cell at the source
Disease control Recruiting nowThis study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficac…
Phase 1/2 • Sponsor: Kamau Therapeutics • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill combo shows promise for tough thyroid cancer
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the BRAFV600E mutation, who are refractory to radioactive iodi…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo pill shows promise for Tough-to-Treat schizophrenia
Disease control CompletedThis is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current atypical antipsychotic treatment. The primary objective of the study is to assess the efficacy of adj…
Phase 3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy aims to outperform standard care in tough colorectal cancer
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic colorectal cancer. The study will also compare MK-4280A with the standard of care treatment of regorafenib and TAS-102 (trifluridine…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a second janssen shot cut severe COVID-19 in south africa?
Vaccine CompletedTo evaluate the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine plus a homologous boostwith Ad26.COV2.S COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonkeparticipants; vaccinated; and unvaccinated populations in South Africa
Phase 3 • Sponsor: Wits Health Consortium (Pty) Ltd • Aim: Vaccine
Last updated Sep 03, 2026 00:00 UTC
-
Can an immunotherapy combo boost remission in a rare lymphoma?
Cure CompletedThe current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of inductive Anti-PD-1+P-GEMOX treatment followed by radiotherapy and concurrent Anti-PD-1 antibody in early-stage Intermediate/High-Risk extranodal NK/T cell lymphoma
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
Gene therapy could free GSD ia patients from constant cornstarch
Disease control CompletedThe primary objectives of this study are to evaluate the efficacy of DTX401 to reduce or eliminate dependence on exogenous glucose replacement therapy to maintain euglycemia and to maintain or improve the quality of glucose control.
Phase 3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for rare, aggressive thyroid cancer: drug combo shows promise
Disease control OngoingThis phase II trial studies how well lenvatinib and pembrolizumab work in treating patients with anaplastic thyroid cancer that is stage IVB and has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable), or stage IVC that has sp…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for older leukemia patients: targeted drug combo shows promise
Disease control OngoingThe safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab a…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Heart failure pill aims to cut deaths and hospital visits
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Radioactive seeds plus immunotherapy: a new hope for Hard-to-Treat head and neck cancer?
Disease control Recruiting nowA unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma
Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC